S-1/A: Picard Medical Files Amendment No. 1 to Form S-1 for IPO, Targeting Expansion and New Product Development

Picard Medical, a medical technology company focused on artificial hearts, has filed an amendment to its S-1 registration statement, signaling progress towards its initial public offering and outlining plans for market expansion and product innovation.

Summary

• Picard Medical, Inc., a holding company for SynCardia Systems, LLC, filed Amendment No. 1 to its Form S-1 registration statement with the SEC on April 24, 2025, regarding its initial public offering.
• SynCardia manufactures and sells the SynCardia TAH, an FDA and Health Canada-approved implantable total artificial heart, used as a bridge to heart transplantation.
• The company's future vision includes developing a fully implantable SynCardia TAH as an alternative to heart transplantation.
• Near-term product development focuses on expanding the indications for use to include Bridge to Candidacy (BTC) and long-term use (2+ years).
• The company plans to expand product sales into more international markets, including China, Taiwan, the Gulf region, India, and Brazil.
• The next-generation Emperor Total Artificial Heart is under development, with animal studies planned for the first half of 2025 and potential FDA approval targeted for 2028.
• The company is also working on upgraded driver systems, with FDA approval for Freedom+ expected in the second half of 2025.
• A field correction related to cannula tears has been initiated, with a design change submission to the FDA expected in the third quarter of 2025.
• The company estimates the net proceeds from the IPO will be approximately $ million, which will be used to support market expansion, fund research and development, build sales and marketing capabilities, and for general operational expenses.
• The company has a history of operating losses and expects to continue incurring significant expenses and operating losses for the foreseeable future.
• There is substantial doubt about the company's ability to continue as a going concern without raising additional capital.
• The company is an emerging growth company and a smaller reporting company, which allows for certain exemptions from public company reporting requirements.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While it highlights the company's unique position and future growth plans, it also acknowledges the company's history of operating losses, the need for additional capital, and the risks associated with regulatory approvals and competition.

Positives

• The SynCardia TAH is the only FDA and Health Canada-approved total artificial heart.
• The company has extensive clinical experience with over 2,100 implants to date.
• The company is actively working on expanding indications for use and developing next-generation products.
• The company has a clear plan for using the proceeds from the IPO to support growth and innovation.

Negatives

• The company has a history of operating losses and expects to continue incurring significant expenses and operating losses.
• There is substantial doubt about the company's ability to continue as a going concern without raising additional capital.
• The company voluntarily withdrew its CE mark in Europe and is working to reinstate it under the new MDR regulations.
• Many aspects of the SynCardia TAH are no longer protected by patents.

Risks

• The company may not be able to achieve and sustain profitability.
• The company relies on specialized suppliers and does not have second-source suppliers for the majority of components.
• The company's future success depends on its ability to develop and receive regulatory approval for new products and product enhancements.
• The company may need to undertake additional clinical trials to secure an expansion of the indication for the SynCardia TAH.
• Failure to reinstate the CE certificate under CE MDR could have a material adverse effect on the business.
• The company may be subject to product liability claims.
• The company's share price may be volatile, and purchasers of securities could incur substantial losses.
• An active trading market may not develop or be sustained.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it continues to sell and market, research and develop and seek regulatory approvals for existing and future products. The company expects to incur additional expenses with transitioning to, and operating as, a public company.

Industry Context

The document provides an overview of the heart failure treatment landscape, highlighting the demand for heart transplants exceeding the available supply and the competition from alternative therapies like LVADs. It positions the SynCardia TAH as a complementary treatment alternative to LVADs and emphasizes the company's competitive advantages.

Comparison to Industry Standards

• The SynCardia TAH is compared to the Carmat Aeson device and the BiVACOR total artificial heart, highlighting differences in approval status, ventricle blood volume, total implant size, number of implants, and implant weight.
• The document notes that the SynCardia TAH is the only total artificial heart approved for commercial use in the United States and Canada.
• The Carmat Aeson device is approved for commercial use in the EU only (CE mark).
• The BiVACOR system has not obtained approval for any market to date.

Related Party Transactions

• Between June 2023 and June 2024, the company borrowed a total of $9,320,000 from Hunniwell and Richard Fang, Fang Family Fund, LLC and Fang Family Fund II, LLC (Fang Family Funds).
• On September 25, 2023, the remaining $300,000 from Hunniwell was settled under a loan agreement which bears 6% interest per annum and matures after two years.
• On July 2, 2024, the remaining $6,990,000 plus interest of $56,090 from Fang Family Funds, was consolidated into one loan with a total principal amount of $7,046,090.
• On November 12, 2024, The Fang Family Funds convertible note, and the related accrued interest was donated to the unrelated not-for-profit organizations, Nexus Science Foundation Inc. (Nexus), and Another Dimension Foundation (Another Dimension).
• Between June 25 and December 31, 2024, in order to meet short-term funding requirements, we borrowed $5,070,000 and $250,000 from Fang Family Fund II, LLC, an entity affiliated with one of our executive directors and Hunniwell, respectively.

Stakeholder Impact

• Shareholders may experience dilution upon the occurrence of certain events, including conversion of Series A-1 Preferred Shares and certain related party loans into shares of common stock.
• The company's ability to attract and retain highly qualified personnel is critical to its success.
• The company's success depends on its ability to develop, receive regulatory approval for, and introduce new products or product enhancements that will be accepted by the market in a timely manner.

Next Steps

• Conduct acute animal studies using selected Emperor design prototypes during the first half of 2025.
• Submit a design change to address the cannula tears to the FDA via a 180 Day PMA Supplement in approximately the third quarter of 2025.
• Reapply for an MDR CE mark during 3Q25.
• Continue to develop upgraded driver systems for both hospital and home use.
• Perform first-in-animal trials of the Emperor system in the first half of 2025.

Key Dates

Keywords

SynCardia TAH, total artificial heart, artificial heart, heart failure, medical device, IPO, FDA, BTT, BTC, Emperor, Freedom Driver, PMA, MDR, Hunniwell, SynCardia